Extranodal NK/T-cell lymphoma, nasal-type, revealed by cutaneous breast involvement;Localisation cutanée mammaire révélatrice d'un lymphome T/NK extranodal de type nasal

Annales de Dermatologie et de Venereologie

Volumn 142, Issue 2, 2015, Pages 104-111

  Freling E ^a   Granel Brocard, F ^a   Serrier, C ^a   Ortonne, N ^b   Barbaud, A ^a   Schmutz, J L ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

Cutaneousinvolvement; Extranodal NK T celllymphoma; Nasal type

Indexed keywords

ASPARAGINASE; DEXAMETHASONE; GEMCITABINE; GRANZYME B; METHOTREXATE; OXALIPLATIN; PERFORIN; VIRUS DNA;

ARTICLE; BLOOD; BONE; BONE MARROW; BREAST; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DUODENUM; EPSTEIN BARR VIRUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY; LUNG; LYMPHOCYTE; MULTIPLE ORGAN FAILURE; NATURAL KILLER CELL; NK T CELL LYMPHOMA; PLEURA CAVITY; POLYMERASE CHAIN REACTION; STOMACH; TREATMENT RESPONSE; UTERUS; ADULT; BREAST TUMOR; PATHOLOGY; SKIN TUMOR;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, EXTRANODAL NK-T-CELL; SKIN NEOPLASMS;

EID: 84922326079     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2014.11.007     Document Type: Article

References (46)

1. Suzuki R, Takeuchi K, Ohshima K, Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment clues. Hematol Oncol2008;26:66-72.
2. A clinical evaluation of the International Lymphoma StudyGroup classification of non-Hodgkin's lymphoma. TheNon-Hodgkin's Lymphoma Classification Project. Blood1997;89:3909-18.
3. The world health organization classification of malignant lym-phomas in japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int2000;50:696-702.
4. William BM, Armitage JO. International analysis of the fre-quency and outcomes of NK/T-cell lymphomas. Best Pract ResClin Haematol 2013;26:23-32.
5. Al-Hakeem DA, Fedele S, Carlos R, Porter S. Extranodal NK/T-cell lymphoma, nasal-type. Oral Oncol 2007;43:4-14.
6. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, KimWS, Song I, et al. Clinical differences between nasal and extra-nasal natural killer/T-cell lymphoma: a study of 136 cases fromthe International Peripheral T-Cell Lymphoma Project. Blood2009;113:3931-7.
7. Swerdlow SH, International Agency for Research on Cancer,World Health Organization. WHO classification of tumours ofhaematopoietic and lymphoid tissues. Lyon, France: Interna-tional Agency for Research on Cancer; 2008.
8. Suzuki R, Suzumiya J, Nakamura S, Aoki S, Notoya A, Ozaki S,et al. Aggressive natural killer-cell leukemia revisited: largegranular lymphocyte leukemia of cytotoxic NK-cells. Leukemia2004;18:763-70.
9. Mansoor A, Pittaluga S, Beck PL, Wilson WH, Ferry JA, JaffeES. NK-cell enteropathy: a benign NK-cell lymphoprolifera-tive disease mimicking intestinal lymphoma: clinicopathologicfeatures and follow-up in a unique case series. Blood2011;117:1447-52.
10. Tefferi A, Li CY, Witzig TE, Dhodapkar MV, Okuno SH, Phyliky RL. Chronic natural killer-cell lymphocytosis: a descriptive clinicalstudy. Blood 1994;84:2721-5.
11. Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, KameokaJ, Kojima H, et al. Prognostic factors for mature naturalkiller (NK) cell neoplasms: aggressive NK-cell leukemiaand extranodal NK-cell lymphoma, nasal-type. Ann Oncol2010;21:1032-40.
12. Vazquez A, Khan MN, Blake DM, Sanghvi S, Baredes S, Eloy JA. Extranodal natural killer/T-Cell lymphoma: a population-basedcomparison of sinonasal and extra-nasal disease. Laryngoscope2014;124:888-95.
13. Xu PP, Wang Y, Shen Y, Wang L, Shen ZX, Zhao WL. Prognosticfactors of Chinese patients with T/NK-cell lymphoma: a singleinstitution study of 170 patients. Med Oncol 2012;29:2176-82.
14. Li S, Feng X, Li T, Zhang S, Zuo Z, Lin P, et al. Extranodal NK/T-cell lymphoma, nasal-type: a report of 73 cases at MD AndersonCancer Center. Am J Surg Pathol 2013;37:14-23.
15. Choi YL, Park JH, Namkung JH, Lee JH, Yang JM, Lee ES, et al. Extranodal NK/T-cell lymphoma with cutaneous involvement:''nasal'' vs ''nasal-type'' subgroups-a retrospective study of18 patients. Br J Dermatol 2009;160:333-7.
16. Bekkenk MW, Jansen PM, Meijer CJ, Willemze R. CD56+ hema-tological neoplasms presenting in the skin: a retrospectiveanalysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004;15:1097-108.
17. Berti E, Recalcati S, Girgenti V, Fanoni D, Venegoni L, VezzoliP. Cutaneous extranodal NK/T-cell lymphoma: a clinicopatho-logic study of 5 patients with array-based comparative genomichybridization. Blood 2010;116:165-70.
18. Zuriel D, Fink-Puches R, Cerroni L. A case of primary cuta-neous extranodal natural killer/t-cell lymphoma, nasal-type,with a 22-year indolent clinical course. Am J Dermatopathol2012;34:194-7.
19. Fried I, Artl M, Cota C, Müller H, Bartolo E, Boi S, et al. Clini-copathologic and molecular features in cutaneous extranodalnatural killer-/T-cell lymphoma, nasal-type, with aggressiveand indolent course. J Am Acad Dermatol 2014;70:716-23.
20. Ng SB, Lai KW, Murugaya S, Lee KM, Loong SLE, Fook-Chong S,et al. Nasal-type extranodal natural killer/T-cell lymphomas: aclinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol 2004;17:1097-107.
21. Hasserjian R, Harris N. NK-Cell lymphomas and leukemias: aspectrum of tumors with variable manifestations and immuno-phenotype. Am J Clin Pathol 2007;127:860-8.
22. Mitarnun W, Suwiwat S, Pradutkanchana J. Epstein-Barrvirus-associated extranodal non-Hodgkin's lymphoma of thesinonasal tract and nasopharynx in Thailand. Asian Pac J CancerPrev 2006;7:91.
23. Tien HF, Su IJ, Tang JL, Liu MC, Lee FY, Chen YC, et al. Clonal chromosomal abnormalities as direct evidence for clo-nality in nasal T/natural killer-cell lymphomas. Br J Haematol1997;97:621-5.
24. Wong KF, Chan JK, Kwong YL. Identification of del(6)(q21q25)as a recurring chromosomal abnormality in putative NK-celllymphoma/leukaemia. Br J Haematol 1997;98:922-6.
25. Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AKW, et al. Clini-copathologic features and treatment outcome of mature T-celland natural killer-cell lymphomas diagnosed according to theWorld Health Organization classification scheme: a single cen-ter experience of 10 years. Ann Oncol 2005;16:206-14.
26. Iqbal J, Kucuk C, Deleeuw RJ, Srivastava G, Tam W,Geng H, et al. Genomic analyses reveal global functionalalterations that promote tumor growth and novel tumor-suppressor genes in natural killer-cell malignancies. Leukemia2009;23:1139-51.
27. Karube K, Nakagawa M, Tsuzuki S, Takeuchi I, Honma K,Nakashima Y, et al. Identification of FOXO3 and PRDM1 as tumor-suppressor gene candidates in NK-cell neoplasms bygenomic and functional analyses. Blood 2011;118:3195-204.
28. Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, KnowlesDM. Mutational analysis of PRDM1 indicates a tumor-suppressorrole in diffuse large B-cell lymphomas. Blood 2006;107:4090-100.
29. Kücük C, Iqbal J, Hu X, Gaulard P, De Leval L, Srivastava G,et al. PRDM1 is a tumor-suppressor gene in natural killer-cellmalignancies. Proc Natl Acad Sci U S A 2011;108:20119-24.
30. Huang Y, de Leval L, Gaulard P. Molecular underpinning ofextranodal NK/T-cell lymphoma. Best Pract Res Clin Haematol2013;26:57-74.
31. Suzuki R. Pathogenesis and treatment of extranodal naturalkiller/T-Cell lymphoma. Semin Hematol 2014;51:42-51.
32. Chan KA, Zhang J, Chan AT, Lei KI, Leung S-F, Chan LY,et al. Molecular characterization of circulating EBV-DNA in theplasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003;63:2028-32.
33. Au W-Y. Quantification of circulating Epstein-Barr virus (EBV)DNA in the diagnosis and monitoring of natural killer-cell andEBV-positive lymphomas in immunocompetent patients. Blood2004;104:243-9.
34. Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K,Harabuchi Y, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclearcells of extranodal NK/T-cell lymphoma, nasal-type. Blood2011;118:6018-22.
35. Ito Y, Kimura H, Maeda Y, Hashimoto C, Ishida F, Izutsu K, et al. Pretreatment EBV-DNA copy number is predictive of responseand toxicities to SMILE chemotherapy for extranodal NK/T-celllymphoma, nasal-type. Clin Cancer Res 2012;18:4183-90.
36. Yamaguchi M, Kita K, Miwa H, Nishii K, Oka K, Ohno T, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-celllymphoma cells. Cancer 1995;76:2351-6.
37. Egashira M, Kawamata N, Sugimoto K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally expandednatural killer-cells and inhibition of P-glycoprotein func-tion by cyclosporin A and its analogue, PSC833. Blood1999;93:599-606.
38. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y,Isobe Y, et al. Phase I/II study of concurrent chemoradio-therapy for localized nasal natural killer/T-cell lymphoma:Japan clinical oncology group study JCOG0211. J Clin Oncol2009;27:5594-600.
39. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y,Isobe Y, et al. Concurrent chemoradiotherapy for localizednasal natural killer/T-cell lymphoma: an updated analysis ofthe Japan clinical oncology group study JCOG0211. J Clin Oncol2012;30:4044-6.
40. Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, et al. Trial ofconcurrent radiation and weekly cisplatin followed by VIPDchemotherapy in newly diagnosed, stage IE to IIE, nasal, extra-nodal NK/T-Cell lymphoma: consortium for improving survivalof lymphoma study. J Clin Oncol 2009;27:6027-32.
41. Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, et al. SMILE for natural killer/T-cell lymphoma: analysis of safetyand efficacy from the Asia Lymphoma Study Group. Blood2012;120:2973-80.
42. Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F,et al. Efficacy of L-asparaginase with methotrexate and dexa-methasone (AspaMetDex regimen) in patients with refractoryor relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011;117:1834-9.
43. Wen JY, Li M, Li X, Chen J, Lin Q, Ma XK, et al. Efficacy and tole-rance of pegaspargase-based chemotherapy in patients withnasal-type extranodal NK/T-cell lymphoma: a pilot study. AsianPac J Cancer Prev 2014;15:6275-81.
44. Chien WW, Allas S, Rachinel N, Sahakian P, Julien M, Le BeuxC, et al. Pharmacology, immunogenicity, and efficacy of anovel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase. Invest New Drugs 2014;32:795-805.
45. Salzer WL, Asselin BL, Plourde PV, Corn T, Hunger SP. Develop-ment of asparaginase Erwinia chrysanthemi for the treatmentof acute lymphoblastic leukemia. Ann N Y Acad Sci 2014,http://dx. doi. org/10. 1111/nyas. 12496 [Epud ahead of print].
46. Liang R. Advances in the management and monitoring ofextranodal NK/T-cell lymphoma, nasal-type. Br J Haematol2009;147:13-21.